Curileum is raising £1.5m on a £12m pre-money valuation to enable negotiation of favourable licensing terms with major pharma companies for its two novel preclinical candidates:

ULI-015 | Novel small molecule to reduce polyp formation and progression to bowel cancer

ATZ stem cell therapy | More effective healing of Crohn's fistulising disease

Average licensing terms: $5m upfront and up to $250m for future payments on marketed therapeutics.